MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today the completion of an oversubscribed $102 million Series D financing. The round was led by Alpha Wave Ventures, a world leader in growth stage investments, with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation - JJDC, Inc.

明尼阿波利斯--（商业新闻短讯）--爱迪生®Histotripsy系统和新型Histotripsy治疗平台的制造商HistoSonics今天宣布完成超额认购的1.02亿美元D系列融资。本轮投资由成长期投资领域的全球领先企业Alpha Wave Ventures牵头，新投资者Amzak Health and HealthQuest Capital以及现有投资者Johnson&Johnson Innovation-JJDC，Inc.参与。

(JJDC), Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board, and others..

（JJDC）、风险投资者、Lumira Ventures、Yonjin Venture、威斯康星州投资委员会等。

Histotripsy is a novel form of focused ultrasound that uses high amplitude, very short pulses to create a “bubble cloud” that is designed to mechanically destroy and liquefy targeted liver tumors. These bubble clouds form and collapse in microseconds, creating mechanical forces strong enough to destroy tissue at cellular and sub-cellular levels in a non-invasive and non-thermal method.

。这些气泡云在几微秒内形成并塌陷，产生足够强的机械力，以非侵入性和非热方法破坏细胞和亚细胞水平的组织。

Histotripsy offers a promising alternative to treatments such as surgery, radiation and chemotherapy, which often have significant side effects..

组织碎石术为手术，放疗和化疗等治疗提供了一种有前途的替代方法，这些治疗通常会产生明显的副作用。

The Series D funding will be used to accelerate category defining advancements to its non-invasive histotripsy platforms, support commercial growth in the US and in planned global markets, and initiate the company’s innovative, prospective BOOMBOX Master Study that will evaluate HistoSonics’ Edison System for the treatment of liver tumors across multidisciplinary users.

D系列资金将用于加速其非侵入性组织学平台的类别定义进步，支持美国和计划中的全球市场的商业增长，并启动该公司的创新性，前瞻性BOOMBOX Master研究，该研究将评估HistoSonics的Edison系统，用于跨多学科用户治疗肝肿瘤。

The Edison Histotripsy System was granted FDA De Novo clearance in October 2023. HistoSonics is currently partnering with leading institutions across the US and internationally in developing multi-disciplinary histotripsy liver programs..

爱迪生组织检查系统于2023年10月获得FDA从头批准。HistoSonics目前正在与美国和国际上的领先机构合作，开发多学科的组织学肝脏项目。

“Histotripsy is a paradigm-changing treatment option for patients who want a non-invasive approach to target and destroy tumors without the need for needles or incisions,” said Mike Blue, President & CEO, HistoSonics. “We’re thrilled to announce this top-tier investor syndicate led by Alpha Wave, which reinforces the confidence in our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types.

HistoSonics总裁兼首席执行官迈克·布鲁（MikeBlue）表示：“对于那些希望采用无创方法靶向和破坏肿瘤而无需针头或切口的患者，组织学检查是一种改变治疗模式的选择。”。“我们很高兴宣布由Alpha Wave领导的这一顶级投资者财团，它增强了我们的信心，我们的使命是通过目前的肝脏应用影响患者的生活，并扩大在肾脏、胰腺、前列腺、大脑和其他肿瘤类型的应用。

This funding will accelerate key projects designed to enhance core technical capabilities impacting current and future platforms, and support collaboration with physicians and researchers studying innovative ways to use histotripsy’s unique mechanism of action to improve patient outcomes. By pioneering a new category of medicine with histotripsy, HistoSonics is redefining liver tumor treatment and providing hope for millions of people worldwide who desperately need new options.”.

这笔资金将加速旨在增强影响当前和未来平台的核心技术能力的关键项目，并支持与医生和研究人员合作，研究创新方法，利用组织学独特的作用机制改善患者预后。HistoSonics开创了一种新的组织病理学医学，正在重新定义肝肿瘤的治疗方法，并为全球数百万迫切需要新选择的人提供希望。”

“Alpha Wave is proud to lead the investment in HistoSonics, a pioneer in the use of histotripsy,” said Chris Dimitropoulos, Managing Director, Healthcare Investments at Alpha Wave Global. “Histotripsy’s unique non-invasive approach uses focused ultrasound to precisely target and destroy diseased tissue without damaging surrounding healthy tissue.

Alpha Wave Global医疗保健投资董事总经理克里斯·迪米特罗普洛斯（ChrisDimitropoulos）表示：“Alpha Wave很自豪能够领导HistoSonics的投资，HistoSonics是使用histotripsy的先驱。”。“Histotripsy独特的非侵入性方法使用聚焦超声波精确定位和破坏病变组织，而不会损害周围的健康组织。

This groundbreaking technology has the potential to transform the treatment landscape for a variety of challenging clinical conditions, offering patients improved outcomes and recovery times. The level of adoption we’ve seen from leading hospital centers across the country and overseas highlights the huge unmet medical need.

这项开创性的技术有可能改变各种具有挑战性的临床状况的治疗格局，为患者提供改善的结果和恢复时间。我们从全国和海外领先的医院中心看到的采用程度突出了巨大的未满足的医疗需求。

We are excited to support HistoSonics in accelerating the development and availability of this innovative therapy.” In connection with this financing, Mr. Dimitropoulos will join the HistoSonics Board of Directors..

我们很高兴支持HistoSonics加速这种创新疗法的开发和可用性。”关于此次融资，Dimitropoulos先生将加入HistoSonics董事会。

HistoSonics' Edison System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control. The novel mechanism of action of this proprietary technology may provide significant patient advantages, including the ability of the treatment site to recover and resorb quickly.

HistoSonics的Edison系统使用专有技术和先进的成像技术，以精确和可控的方式提供个性化的非侵入性组织分解治疗。这种专有技术的新型作用机制可能会为患者提供显着的优势，包括治疗部位快速恢复和再吸收的能力。

HistoSonics’ platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today..

HistoSonics的平台还为医生提供了在连续实时可视化和控制下监测组织破坏的能力，这与当今存在的任何模式不同。

About HistoSonics

关于组织超声学

HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others.

HistoSonics是一家私营医疗器械公司，利用组织分解科学开发非侵入性平台和专有声束疗法，这是一种使用聚焦超声波机械破坏和液化不需要的组织和肿瘤的新型作用机制。该公司目前专注于在美国将爱迪生系统商业化，并选择全球肝脏治疗市场，同时将组织分解术的应用扩展到其他器官，如肾脏、胰腺、前列腺、大脑等。

HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota. The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any specific disease or condition.

HistoSonics在密歇根州的安娜堡和明尼苏达州的明尼阿波利斯设有办事处。Edison®系统用于肝肿瘤的非侵入性机械破坏，包括通过组织切片术部分或完全破坏不可切除的肝肿瘤。FDA尚未评估爱迪生系统治疗任何特定疾病或病症的效果。

Patients seeking information on histotripsy and if they may be a candidate for histotripsy can learn more at www.myhistotripsy.com..

寻求组织学检查信息的患者，如果他们可能是组织学检查的候选人，可以在www.myhistotripsy.com上了解更多信息。

Use of the Edison System in kidney applications is limited by federal law to investigational use. The #HOPE4KIDNEY Trial is designed to support a future expansion of the indication to include the destruction of kidney tissue/tumors.

爱迪生系统在肾脏应用中的使用受到联邦法律的限制，仅限于研究用途。#HOPE4KIDNEY试验旨在支持适应症的未来扩展，包括破坏肾组织/肿瘤。

About Alpha Wave

关于Alpha Wave

Alpha Wave is a global investment company with three main verticals: private equity, private credit, and public markets. It is led by Rick Gerson, Navroz Udwadia, and Ryan Khoury. Its flagship global private equity fund, Alpha Wave Ventures, aims to invest in best-in-class growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams..

Alpha Wave是一家全球性投资公司，拥有三大垂直领域：私募股权、私人信贷和公共市场。它由里克·格森、纳夫罗兹·乌德瓦迪亚和瑞安·霍里领导。其旗舰全球私募股权基金Alpha Wave Ventures旨在投资一流的成长阶段公司，并努力成为创始人和管理团队的长期合作伙伴。

Alpha Wave has offices in Miami, New York, London, Monaco, Madrid, Abu Dhabi, Tel Aviv, Bangalore, and Sydney. For more information, please visit www.alphawaveglobal.com.

Alpha Wave在迈阿密、纽约、伦敦、摩纳哥、马德里、阿布扎比、特拉维夫、班加罗尔和悉尼设有办事处。有关更多信息，请访问www.alphawaveglobal.com。

For more information please visit: www.histosonics.com/

有关更多信息，请访问：www.histosonics.com/